{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:35:14Z","timestamp":1763037314355},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00508-019-1487-4","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T08:03:57Z","timestamp":1555056237000},"page":"141-150","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Diabetische Neuropathie und diabetischer Fu\u00df (Update 2019)"],"prefix":"10.1007","volume":"131","author":[{"given":"Monika","family":"Lechleitner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidemarie","family":"Abrahamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Kofler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"Suppl 1","key":"1487_CR1","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.2337\/dc18-S010","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Microvascular complications and foot care. Standards of Medical Care in Diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S105\u2013S18.","journal-title":"Diabetes Care"},{"key":"1487_CR2","first-page":"24","volume":"1","author":"D Ziegler","year":"1992","unstructured":"Ziegler D, Gries FA. Epidemiologie der peripheren diabetischen Neuropathie. Diabetes Stoffwechs. 1992;1:24\u20138.","journal-title":"Diabetes Stoffwechs"},{"key":"1487_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","volume":"11","author":"BC Callaghan","year":"2012","unstructured":"Callaghan BC, Cheng HAT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatment. Lancet Neurol. 2012;11:521\u201334.","journal-title":"Lancet Neurol"},{"key":"1487_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00400697","volume":"36","author":"MJ Young","year":"1993","unstructured":"Young MJ, Boulton AJM, Mac IEO, et\u00a0al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital population. Diabetologia. 1993;36:150\u20134.","journal-title":"Diabetologia"},{"key":"1487_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1526-4637.2008.00555.x","volume":"10","author":"D Ziegler","year":"2009","unstructured":"Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA\/KORA Augsburg Survey S2 and S3. Pain Med. 2009;10:393\u2013400.","journal-title":"Pain Med"},{"key":"1487_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2337\/dc11-1108","volume":"34","author":"CA Abbott","year":"2011","unstructured":"Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boultin AJ. Prevalence and characteristics of painful diabetic neuropathy in a\u00a0large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220\u20134.","journal-title":"Diabetes Care"},{"key":"1487_CR7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285\u201393.","journal-title":"Diabetes Care"},{"key":"1487_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.diabet.2008.09.003","volume":"35","author":"V Guastella","year":"2009","unstructured":"Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabetes Metab. 2009;35:12\u20139.","journal-title":"Diabetes Metab"},{"key":"1487_CR9","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.2337\/dc05-2228","volume":"29","author":"M Davies","year":"2006","unstructured":"Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518\u201322.","journal-title":"Diabetes Care"},{"key":"1487_CR10","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1212\/WNL.42.6.1164","volume":"42","author":"PJ Dyck","year":"1992","unstructured":"Dyck PJ, Karnes JL, O\u2019Brien PC, et\u00a0al. The Rochester diabetic neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164\u201370.","journal-title":"Neurology"},{"key":"1487_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/WNL.43.4.817","volume":"43","author":"PJ Dyck","year":"1993","unstructured":"Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a\u00a0population-based cohort: the Rochester diabetic neuropathy study. Neurology. 1993;43:817\u201324.","journal-title":"Neurology"},{"key":"1487_CR12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.2337\/diab.38.11.1456","volume":"38","author":"RE Maser","year":"1989","unstructured":"Maser RE, Steenkiste AR, Dorman JS, et\u00a0al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh epidemiology of diabetes complication study. Diabetes. 1989;38:1456\u201361.","journal-title":"Diabetes"},{"key":"1487_CR13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1464-5491.2002.00778.x","volume":"19","author":"LV Pollyranse Van de","year":"2003","unstructured":"Van de Pollyranse LV, Valk GD, Renders CM, Heine RJ, Eijk JTM. Longitudinal assessment of the development of diabetic polyneuropathies and associated risk factors. Diabet Med. 2003;19:771\u20139.","journal-title":"Diabet Med"},{"issue":"Suppl 1","key":"1487_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/dmrr.2239","volume":"28","author":"S Tesfaye","year":"2012","unstructured":"Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic neuropathy. Diabetes Metab Res Rev. 2012;28(Suppl 1):8\u201314.","journal-title":"Diabetes Metab Res Rev"},{"key":"1487_CR15","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s001250051227","volume":"42","author":"AA Sima","year":"1999","unstructured":"Sima AA, Sugimoto K. Experimental diabetic neuropathy. An update. Diabetologia. 1999;42:773\u201388.","journal-title":"Diabetologia"},{"key":"1487_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2011.137","volume":"7","author":"AM Vincent","year":"2011","unstructured":"Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanism as therapeutic targets. Nat Rev Neurol. 2011;7:573\u201383.","journal-title":"Nat Rev Neurol"},{"key":"1487_CR17","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1093\/brain\/124.12.2448","volume":"124","author":"S Yagihashi","year":"2001","unstructured":"Yagihashi S, Yamagishi SI, Wada RI, et\u00a0al. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain. 2001;124:2448\u201358.","journal-title":"Brain"},{"key":"1487_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10286-010-0084-4","volume":"21","author":"RD Hoeldike","year":"2011","unstructured":"Hoeldike RD, Bryner KD, Van Dyke K. Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res. 2011;21:19\u201328.","journal-title":"Clin Auton Res"},{"key":"1487_CR19","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1210\/jc.2008-2385","volume":"94","author":"J Doupis","year":"2009","unstructured":"Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J\u00a0Clin Endocrinol Metab. 2009;94:2157\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1487_CR20","first-page":"216","volume":"3","author":"D Ziegler","year":"2011","unstructured":"Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr Diab Rep. 2011;3:216\u201327.","journal-title":"Curr Diab Rep"},{"key":"1487_CR21","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2337\/diacare.26.5.1553","volume":"26","author":"AI Vinik","year":"2003","unstructured":"Vinik AI, Maser RE, Mitchell BD, Freema R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553\u201379.","journal-title":"Diabetes Care"},{"key":"1487_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/dmrr.1225","volume":"27","author":"S Tesfaye","year":"2011","unstructured":"Tesfaye S, Vileikyte L, Rayman G, et\u00a0al. On behalf of the toronto expert panel on diabetic neuropathy. Diabetes Metab Res Rev. 2011;27:629\u201338.","journal-title":"Diabetes Metab Res Rev"},{"key":"1487_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ptj\/76.1.68","volume":"76","author":"MJ Mueller","year":"1996","unstructured":"Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther. 1996;76:68\u201371.","journal-title":"Phys Ther"},{"key":"1487_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2337\/diacare.26.3.697","volume":"26","author":"JW Meijer","year":"2003","unstructured":"Meijer JW, Bosma E, Leprandt JD, Links TP, Smit AJ, Stewart RE, Van Der Hoeven JH, Hoogenberg K. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptoms and diabetic neuropathy examination score. Diabetes Care. 2003;26:697\u2013701.","journal-title":"Diabetes Care"},{"key":"1487_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1464-5491.2003.00931.x","volume":"20","author":"M Rahman","year":"2003","unstructured":"Rahman M, Griffin SJ, Rathman W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-bases comparison of four measures. Diabet Med. 2003;20:368\u201374.","journal-title":"Diabet Med"},{"key":"1487_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.20785","volume":"36","author":"DW Zochodne","year":"2007","unstructured":"Zochodne DW. Diabetes mellitus and the peripheral nervous system: Manifestations and mechanisms. Muscle Nerve. 2007;36:144\u201366.","journal-title":"Muscle Nerve"},{"key":"1487_CR27","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/diacare.17.11.1281","volume":"17","author":"EL Feldman","year":"1994","unstructured":"Feldman EL. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281\u20139.","journal-title":"Diabetes Care"},{"key":"1487_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/mus.22092","volume":"43","author":"V Bril","year":"2011","unstructured":"Bril V, England JD, Franklin GM, Backonja M, Cohen JA, Del Toro DR, Feldman EL, Iverson DJ, Perkins B, Russell JW, Zochodne DW. Evidence-based guideline: treatment of painful diabetic neuropathy\u2014report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine& Rehabilitation. Muscle Nerve. 2011;43:910\u20137.","journal-title":"Muscle Nerve"},{"key":"1487_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00004691-199711000-00011","volume":"14","author":"CF Bolton","year":"1997","unstructured":"Bolton CF, Remtulla H, Toth B, Bernardi L, Lindsay RM, Maryniak O, Burton SR. Distinctive electrophysiological features of denervated muscle in uremic patients. J\u00a0Clin Neurophysiol. 1997;14:539\u201342.","journal-title":"J Clin Neurophysiol"},{"key":"1487_CR30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/j.1468-1331.2010.03023.x","volume":"17","author":"G Lauria","year":"2010","unstructured":"Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, Nolano M, Merkies ISJ, Polydefkis M, Smith AG, Sommer C, Valls-Sol\u00e9 J. European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a\u00a0joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903\u2013912, e44-9.","journal-title":"Eur J Neurol"},{"key":"1487_CR31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00125-003-1086-8","volume":"46","author":"RA Malik","year":"2003","unstructured":"Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a\u00a0non-invasive surrogate of nerve fibre damage and repair in diabetic patients. Diabetologia. 2003;46:683\u20138.","journal-title":"Diabetologia"},{"key":"1487_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complication Trial Research Group.","year":"1993","unstructured":"Diabetes Control and Complication Trial Research Group.. The effects of intensive treatment of diabetes on the development and progressive of long term complications in insulin-dependent diabetes mellitus. N\u00a0Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"1487_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2337\/diacare.29.02.06.dc05-1549","volume":"29","author":"CL Martin","year":"2006","unstructured":"Martin CL, Albers J, Herman WH, et\u00a0al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial. Diabetes Care. 2006;29:340\u20134.","journal-title":"Diabetes Care"},{"key":"1487_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MOT.0b013e32833552bc","volume":"15","author":"C Gremizzi","year":"2010","unstructured":"Gremizzi C, Vergani A, Paloschi V, Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant. 2010;15:119\u201323.","journal-title":"Curr Opin Organ Transplant"},{"key":"1487_CR35","first-page":"837","volume":"12","author":"UK Prospective Diabetes (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and rate of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;12:837\u201363.","journal-title":"Lancet"},{"key":"1487_CR36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethal MA, et al. 10-years follow-up of intensive glucose control in type 2 diabetes. N\u00a0Engl J Med. 2008;359:1577\u201384.","journal-title":"N Engl J Med"},{"key":"1487_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/BF00403376","volume":"37","author":"KF Amthor","year":"1994","unstructured":"Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients. The Oslo study. Diabetologia. 1994;37:579\u201384.","journal-title":"Diabetologia"},{"key":"1487_CR38","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s001250050602","volume":"31","author":"P Reichard","year":"1996","unstructured":"Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose levels:the Stockholm Diabetes Intervention Study (SDIS) at 10-years follow up. Diabetologia. 1996;31:1483\u20138.","journal-title":"Diabetologia"},{"key":"1487_CR39","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","unstructured":"ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N\u00a0Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"1487_CR40","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"8","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, et\u00a0al. Intensive glucose control and complications in American Veterans with type 2 diabetes. N\u00a0Engl J Med. 2009;8:129\u201339.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"1487_CR41","first-page":"255","volume":"31","author":"D Ziegler","year":"2008","unstructured":"Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care. 2008;31(Suppl 2):255\u201361.","journal-title":"Diabetes Care"},{"key":"1487_CR42","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.2337\/dc11-0503","volume":"34","author":"D Ziegler","year":"2011","unstructured":"Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the Nathan 1 trial. Diabetes Care. 2011;34:2054\u201360.","journal-title":"Diabetes Care"},{"key":"1487_CR43","first-page":"377","volume":"7","author":"CE McIlduff","year":"2011","unstructured":"McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377\u201385.","journal-title":"Ther Clin Risk Manag"},{"key":"1487_CR44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1177\/0300060518756540","volume":"46","author":"E Agathos","year":"2018","unstructured":"Agathos E, Tentolouris A, Eleftheriadou I, KAtsaouni P, Nemtzas I, Petrou A, Papanikolaou C, Tentolouris N. Effect of alpha-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J\u00a0Int Med Res. 2018;46:1779\u201390.","journal-title":"J Int Med Res"},{"key":"1487_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdiacomp.2014.08.008","volume":"29","author":"D Ziegler","year":"2015","unstructured":"Ziegler D, Fonseca V. From guideline to patient: a\u00a0review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J\u00a0Diabetes Complicat. 2015;29:146\u201356.","journal-title":"J Diabetes Complicat"},{"key":"1487_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/papr.12054","volume":"14","author":"SJ Snedcor","year":"2014","unstructured":"Snedcor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14:167\u201384.","journal-title":"Pain Pract"},{"key":"1487_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub2.","author":"RA Moore","year":"2009","unstructured":"Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009; \n                    https:\/\/doi.org\/10.1002\/14651858.CD007076.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"1487_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jama.293.2.217","volume":"293","author":"N Singh","year":"2005","unstructured":"Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. J\u00a0Am Med Assoc. 2005;293:217\u201328.","journal-title":"J Am Med Assoc"},{"key":"1487_CR49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2337\/dc17-1836","volume":"41","author":"WJ Jeffcoate","year":"2018","unstructured":"Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current challenges and opportunities in the prevention and management of diabetic foot ulcers. Diabetes Care. 2018;41:645\u201352.","journal-title":"Diabetes Care"},{"key":"1487_CR50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2337\/diacare.22.3.382","volume":"22","author":"SD Ramsey","year":"1999","unstructured":"Ramsey SD, Newton K, Blough D, et\u00a0al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382\u20137.","journal-title":"Diabetes Care"},{"key":"1487_CR51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","volume":"24","author":"EB Jude","year":"2001","unstructured":"Jude EB, Oyibo S, Chalmers N, Boulton AJM. Peripheral arterial disease in diabetic and nondiabetic patients. Diabetes Care. 2001;24:1433\u20137.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1487_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/dmrr.2253","volume":"28","author":"K Bakker","year":"2012","unstructured":"Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):225\u201331.","journal-title":"Diabetes Metab Res Rev"},{"key":"1487_CR53","unstructured":"International Working Group on the Diabetic Foot. 2015. \n                    http:\/\/www.iwgdf.org\/files\/2015\/website_summary.pdf\n                    \n                  . Zugegriffen: 9. Juli 2015."},{"key":"1487_CR54","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2337\/dc08-9017","volume":"31","author":"AJ Boulton","year":"2008","unstructured":"American Diabetes Association, American Association of Clinical Endocrinologists, Boulton AJ, Armstrong DG, Albert SF, et\u00a0al. Comprehensive foot examination and risk assessment: a\u00a0report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31:1679\u201385.","journal-title":"Diabetes Care"},{"key":"1487_CR55","first-page":"762","volume":"39","author":"European Stroke Organization","year":"2018","unstructured":"European Stroke Organization, Aboyans V, Ricco JB, Bartelink ML, Bj\u00f6rck M, Brodmann M, Cohnert T, Collet JP, Czerny M. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Soceity for Vascular Surgery (ESVS). Eur Heart\u00a0J. 2018;39:762\u2013821.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"1487_CR56","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/dmrr.2252","volume":"28","author":"NC Schaper","year":"2012","unstructured":"Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, Mills JL, Reekers J, Shearman CP, Zierler RE, Hinchliffe RJ, et\u00a0al. Specific guidelines for the diagnosis and treatment of peripheral arterial disease in a\u00a0patients with diabetes and ulceration of the foot 2011. Diabetes Metab Res Rev. 2012;28(Suppl 1):236\u20137.","journal-title":"Diabetes Metab Res Rev"},{"key":"1487_CR57","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1055\/s-0041-101257","volume":"140","author":"R Brandl","year":"2015","unstructured":"Brandl R, Stiegler H. Das diabetische Fu\u00dfsyndrom \u2013 Pathogenese, Diagnostik, Therapie und Pr\u00e4vention. Dtsch Med Wochenschr. 2015;140:593\u2013602.","journal-title":"Dtsch Med Wochenschr"},{"key":"1487_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1055\/s-0034-1366455","volume":"122","author":"S Morbach","year":"2014","unstructured":"Morbach S, M\u00fcller E, Reike H, Risse A, R\u00fcmenapf G, Spraul M. Diabetic foot syndrome. Exp Clin Endocrinol Diabetes. 2014;122:416\u201324.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1487_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.17219\/acem\/37020","volume":"23","author":"R Malecki","year":"2014","unstructured":"Malecki R, Rosinski K, Adamiec R. Etiological factors of infections in diabetic foot syndrome\u2014attempt to define optimal empirical therapy. Adv Clin Exp Med. 2014;23:39\u201348.","journal-title":"Adv Clin Exp Med"},{"issue":"Suppl 1","key":"1487_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/dmrr.2246","volume":"28","author":"FL Game","year":"2012","unstructured":"Game FL, Hinchliffe RJ, Apelqvist J, Armstrong DG, Bakker K, Hartemann A, L\u00f6ndahl M, Price PE, Jeffcoate WJ. A Systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2012;28(Suppl 1):119\u201341.","journal-title":"Diabetes Metab Res Rev"},{"key":"1487_CR61","first-page":"439","volume-title":"Levin and O\u2019Neals\u2019s. The diabetic foot","author":"LJ Sanders","year":"2001","unstructured":"Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. In: Bowker JH, Pfeifer MA, Hrsg. Levin and O\u2019Neals\u2019s. The diabetic foot. 6.\u00a0Aufl. St. Louis: CV Mosby; 2001. S.\u00a0439\u201366.","edition":"6"},{"key":"1487_CR62","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cpm.2017.02.008","volume":"34","author":"DJ Short","year":"2017","unstructured":"Short DJ, Zgonis T. Management of osteomyelitis and bone loss in the diabetic charcot foot and ankle. Clin Podiatr Med Surg. 2017;34:381\u20137.","journal-title":"Clin Podiatr Med Surg"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-019-1487-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-019-1487-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T23:19:11Z","timestamp":1586560751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-019-1487-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":62,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1007\/s00508-019-1487-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"12 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Lechleitner hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards erhalten: Boehringer Ingelheim, Novo Nordisk, Sanofi. H.\u00a0Abrahamian hat Vortragshonorare und Honorare f\u00fcr Beratungst\u00e4tigkeit von folgenden Firmen erhalten: Eli Lilly, AstraZeneca, Boehringer Ingelheim, Amgen, Sanofi, Novo Nordisk, Servier, MSD. C.\u00a0Francesconi hat Vortragshonorare und Honorar f\u00fcr Beratungst\u00e4tigkeit von folgenden Firmen erhalten: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Lilly, Sanofi, MSD, Takeda, DEx Com. M.\u00a0Kofler, W.\u00a0Sturm und G.\u00a0K\u00f6hler geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}